U.S. laboratory equipment maker Thermo Fisher Scientific has arrived at an agreement to purchase genetic tests offer firm Qiagen in an $eleven.five billion offer.
At 39 euros per share (about $43.forty two), the funds supply signifies a high quality of roughly 23% to the closing rate of Qiagen on March 2, the organizations reported. It involves the assumption of roughly $one.4 billion of internet personal debt.
Qiagen is a main provider of products and solutions that put together tissue and blood samples for innovative tests, which includes infectious disorder tests.
Very last thirty day period, the firm commenced delivery speedy